About this trial
This study aims to evaluate the efficacy and safety of Remimazolam, either used alone or in combination with Propofol, for moderate sedation anesthesia during endoscopic therapies or examinations. Additionally, it seeks to explore whether their combination can further enhance the quality of patient anesthesia and recovery outcomes.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Subjects are between 20-80 years old.
Anesthesiologists rated ASA as between I and III.
Patients undergoing upper gastrointestinal endoscopic examination or therapy.
Disqualifiers
Allergy to Propofol, Remimazolam, or opioid medications.
Emergency surgery.
Pregnancy.
History of malignant hyperthermia.
Trial design
Parallel
Treatments tested in this trial
Remimazolam
DrugRemimazolam
Propofol
DrugPropofol dose reduction ratio
Treatment groups
Trial outcomes
Primary outcomes
Dose change
Change in Propofol dose ratio. (Record total dose, Duration, mg/h/kg)
Secondary outcomes
Incidence of postoperative nausea and vomiting.
Track postoperative nausea and vomiting episodes.
Time to open eyes after stopping Propofol or Remimazolam.
Eye open minutes after Propofol or Remimazolam stop.
Use of rescue medications during surgery.
Rescue drugs are used during the operation
Analgesic dosage in the recovery room.
Analgesic dosage in the postoperative recovery room.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.